[Federal Register Volume 68, Number 169 (Tuesday, September 2, 2003)]
[Notices]
[Pages 52224-52225]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-22328]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on April 22, 2003, Cambridge 
Isotope Laboratories, Inc., 50 Frontage Road, Andover, Massachusetts 
01801, made application by renewal to the Drug Enforcement 
Administration (DEA) for registration as a bulk manufacturer of the 
basic classes of controlled substances listed below:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Methaqualone (2565)........................  I
Dimethyltryptamine (7435)..................  I
Amphetamine (1100).........................   II
Methamphetamine (1105).....................  II
Pentobarbital (2270).......................  II
Secobarbital (2315)........................  II
Phencyclidine (7471).......................  II
Cocaine (9041).............................  II
Codeine (9050).............................  I
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Benzoylecgonine (9180).....................  II
Methadone (9250)...........................  II
Dextropropoxyphene (9273)..................  II
Morphine (9300)............................  II

[[Page 52225]]

 
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The firm plans to manufacture small quantities of the listed 
controlled substances to produce isotope labeled standards for drug 
analysis.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: Federal Register Representative, 
Office of Chief Counsel (CCD) and must be filed no later than November 
3, 2003.

    Dated: August 19, 2003.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 03-22328 Filed 8-29-03; 8:45 am]
BILLING CODE 4410-09-M